INTRODUCTION

It has been reported that the incidence of thyroid nodule in Graves’ disease patients varies from 10% to 35% (1-9). It is possible that high-resolution ultrasonography during initial diagnosis allowed identification of small thyroid nodules in Graves’ disease patients. However, the prevalence of differentiated thyroid cancer (DTC) in Graves’ disease patients remains as a matter of debate, with previous reports showing the prevalence was 0.3-16.6% (1-14).

The biologic behaviors and optimal management of DTC with concurrent Graves’ disease are still controversial. Some investigators have reported that patients of DTC associated with Graves’ disease experience a more aggressive course than euthyroid patients (15, 16). Pellegriti et al. (17) suggested that the extent of surgery in such patients must be extensive, involving at least a total thyroidectomy and lymph node dissection followed by 131I radioactive iodine therapy (RI). In contrast, others reported that the aggressiveness and the treatment outcomes of DTC in Graves’ disease patients are similar to those of euthyroid patients (6, 18). Thus, there remains controversy as to the optimal extent of surgery in these cases.

The aims of the present study were to identify clinicopathologic features, treatment outcome, and indicators for predicting locoregional recurrence, and to suggest the optimal extent of surgery in DTC patients with concurrent Graves’ disease.
solution (8 drops per 6 hr) for 7 to 10 days before surgery. The indications for surgery were the presence of a large compressive goiter, recurrent thyrotoxicosis, side effects of antithyroid medications, unwillingness or inability of taking medicine, presence of cold nodules on thyroid scanning, and suspicion of malignancy on fine needle aspiration biopsy.

**Diagnostic timing**

Study patients were classified as clinically overt carcinoma or incidental carcinoma. In clinically overt carcinoma, a patient with Graves’ disease was found to have a specific symptom or sign and thyroid carcinoma was diagnosed preoperatively. However, in incidental carcinoma, Graves’ disease was the only clinical diagnosis before operation and thyroid carcinoma was identified during surgery or following histological examination of permanent sections.

**Surgical method**

Patients with incidental carcinoma underwent a bilateral subtotal thyroidectomy or a Hartley-Dunhill operation (16) (a unilateral lobectomy with a contralateral subtotal lobectomy, leaving 4-6 g of thyroid tissue). Intraoperative frozen sections were carried out in all the suspicious lesions. In case of clinical carcinoma, we performed the operative methods according to the TNM classification system (T, tumor size; N, involvement of lymph nodes; M, presence of distant metastasis) (19).

**Postoperative follow-up**

All patients were postoperatively followed up every 3-6 months. Patients were evaluated for locoregional or distant metastasis by the following diagnostic methods: serum thyroglobulin/anti-thyroglobulin antibody level, ultrasonography, computed tomography, radioiodine scintigraphy.  

**Statistical analysis**

Comparisons between groups were performed using Mann-Whitney U test and Fisher’s exact test. Estimated survival rates were calculated by the Kaplan-Meier method. Statistical significance was set at \( p < 0.05 \).

**RESULTS**

**Clinical characteristics**

Fifty-eight cases of DTC (7.4%) were diagnosed among 779 Graves’ disease patients who underwent thyroidectomy between 1986 and 2005. The study enrolled 8 male and 50 female patients with a mean age of 40.8 ± 12.7 yr (range, 15-70). No patients had previous history of radiation exposure or radioactive iodine therapy. Twenty-six cases of clinically overt thyroid carcinomas were diagnosed among 779 Graves’ disease patients (3.3%). The prevalence of incidental carcinoma in the Graves’ disease patients was calculated as 4.2% (32 patients with occult thyroid carcinoma out of 753 patients who underwent operation represented only part of Graves’ disease). Comparison of clinical findings of incidental and clinical carcinoma patients revealed no difference between the two groups in terms of duration of thyrotoxic symptoms, T3/T4 serum levels before the administration of antithyroid medication, and postoperative 6-week serum concentration of thyroglobulin/TSH (Table 1).

**Surgical treatment and histopathologic findings**

Of the 26 patients with clinical carcinoma, 14 underwent total thyroidectomy and 12 underwent subtotal thyroidectomy. Of the 32 patients with incidental carcinoma, 5 underwent total thyroidectomy and 26 subtotal thyroidectomy (Table 2). There was one patient of completion thyroidecto-

### Table 1. Clinical characteristics of clinical and incidental cancers

| Characteristics       | Total (n=58) | Clinical cancer (n=26) | Incidental cancer (n=32) | \( p \) value |
|-----------------------|-------------|------------------------|--------------------------|--------------|
| Gender                |             |                        |                          |              |
| Male                  | 8           | 4                      | 4                        | 0.751*       |
| Female                | 50          | 22                     | 26                       |              |
| Mean age (yr)         | 40.84±12.69 | 42.50±14.87            | 39.50±10.67              | 0.376*       |
| Tumor size (mm)       | 13.14±9.78  | 19.52±14.43            | 7.32±6.76                | 0.017*       |
| Duration of thyrotoxic symptoms (month) | 27.62±26.40 | 29.54±27.90           | 26.06±25.46              | 0.017        |
| Serum T4 (mM/L)\(^1\) | 212.43±13.64 | 226.32±31.46        | 204.19±19.76             | 0.196*       |
| Serum T3 (mM/L)\(^1\) | 7.98±0.76    | 8.02±0.99              | 7.42±0.85                | 0.241*       |
| Thyroglobulin (μg/L)\(^8\) | 13.41±17.35 | 11.540±12.64         | 15.13±10.04              | 0.482*       |
| Serum TSH (mIU/L)\(^7\) | 19.32±21.08 | 22.06±20.19         | 17.78±24.64              | 0.186*       |

Mean±SD; median, with the range presented in parenthesis.  
* Fisher’s exact test; \(^1\), Mann-Whitney test; \(^2\), before antithyroid medication; \(^8\), six-week postoperative serum level.  
T4, thyroxine; T3, triiodothyronine; TSH, thyroid-stimulating hormone.
my, who had initially undergone a subtotal thyroidectomy for Graves’ disease; the subsequent histopathology analysis, however, showed a widely invasive follicular carcinoma. Of the total 58 carcinomas, 57 (98.3%) were papillary thyroid carcinoma and 1 (1.7%) was a follicular thyroid carcinoma. The mean tumor size was $13 \pm 9$ mm in diameter (range, 3-62). Extracapsular invasion and invasion to adjacent structure were found in 23 (39.7%) and 3 cases (5.2%), respectively. Multiple lesions were noted in 18 cases (31.0%). Central compartment node metastasis and lateral cervical lymph node metastasis were shown in 18 (31.0%) and 5 (8.6%) cases, respectively.

**Postoperative adjuvant therapy**

Sixteen patients treated with total thyroidectomy underwent postoperative adjuvant RI. Eleven of these patients

---

**Table 2. Surgical methods**

| Characteristics | Total (n=58) (%) | Clinical cancer (n=26) (%) | Incidental cancer (n=32) (%) |
|-----------------|-----------------|---------------------------|-----------------------------|
| Bilateral subtotal thyroidectomy | 22 (37.9) | 22 (68.8) |
| Dunhill procedure | 4 (6.9) | 4 (12.5) |
| TT with CCND | 14 (24.2) | 9 (34.6) |
| Ipsilateral total and contralateral subtotal thyroidectomy with CCND | 12 (20.7) | 12 (46.2) |
| Total thyroidectomy with MRND | 5 (8.6) | 5 (19.2) |
| Completion thyroidectomy | 1 (1.7) | 1 (3.1) |

TT, total thyroidectomy; MRND, modified radical neck dissection; CCND, central compartment neck dissection.

---

**Table 3. Disease patterns in four locoregional recurrence patients**

| Case 1 | Case 2 | Case 3 | Case 4 |
|--------|--------|--------|--------|
| Gender | F      | F      | F      | F      |
| Age (yr) | 48    | 21    | 61    | 46    |
| Duration of recurrence (months) | 153   | 91    | 167   | 107   |
| Tumor size (mm) | 17    | 9     | 24    | 16    |
| Clinical/incidental | Clinical | Clinical | Clinical | Clinical |
| TNM | T3N1aM0 | T3N1aM0 | T3N0M0 | T3N1bM0 |
| Stage | Stage III | Stage I | Stage III | Stage IVa |
| 1st operation | TT /c CCND | TT /c CCND | TT /c CCND | TT /c MRND |
| Site of LR | Strap muscle | Thyroid bed | Thyroid bed | LCLN |
| Treatment of LR | Reoperation+H-RI | No treatment | Reoperation+H-RI | No treatment |
| Treatment outcome | Remission | Death | Remission | Death |
| Cause of death | Ovary cancer /c SM | LR |

Clinical/incidental, clinical cancer or incidental cancer; TT, total thyroidectomy; /c, with; CCND, central compartment node dissection; MRND, modified radical neck dissection; LR, local recurrence; LCLN, lateral cervical lymph node; H-RI, high-dose radioactive iodine therapy; SM, systemic metastasis.

---

**Fig. 1.** The overall (A) and disease-free (B) survival of patients who underwent surgical treatment for differentiated thyroid carcinoma and concurrent Graves’ disease.
Differentiated Thyroid Cancer in Patients with Graves’ Disease

The mean follow-up period was 116.8 ± 54.0 months (range, 23-260). For all the patients, the 10-yr overall survival and disease-free survival rates were calculated to be 95.8% and 91.1%, respectively (Fig. 1). Local recurrence was identified in 4 patients (6.9%), all of whom belonged to the clinical carcinoma group. The mean duration of recurrence was 129 ± 36 months (range, 91-167), with no patients diagnosed with distant metastases during the follow-up.

Of the 4 loco-regional recurrence patients, 2 patients underwent re-operation and high-dose RI. Neither of these patients has shown any evidence of recurrence up to now (77 months and 54 months, respectively) since the second operation. For the other 2 patients, local recurrence was noted in the thyroid bed and lateral cervical lymph nodes, respectively (Table 3). These patients were not treated for this local recurrence since both refused to undergo treatment: one died of aggressiveness of local recurrence 132 months after the initial thyroidectomy and the other of combined ovary cancer with systemic metastasis 98 months after the surgery.

The patient age of over 45 yr, tumor size, multiplicity, extracapsular invasion, and clinical cancer were significant factors in predicting the locoregional recurrence (Table 4).

DISCUSSION

The prevalence of thyroid carcinoma in Graves’ disease has been reported to be from 0.3% to 16.6% (1-14). It is suggested that part of the explanation for the wide variation in incidence could be due to differences in the extent of resection as well as in the number of histologic sections examined per specimen (20). Moreover, the increasing use of high resolution ultrasonography has revealed greater numbers of thyroid nodules, and the routine use of such devices has allowed diagnosis of small thyroid carcinoma in Graves’ disease patients. The 7.4% prevalence found in our work seems to be relevant to that found in other reports.

Controversy remains regarding the pathogenic relationship between thyroid carcinoma and Graves’ disease. It is well known that the binding of TSH to TSH receptors might promote the growth of cancer cells in euthyroid patients with thyroid carcinoma. In Graves’ disease in which serum TSH is suppressed, TSAbs rather than TSH are reported to activate the TSH receptor (16, 21, 22). Some studies showed that autoimmune responses in Graves’ disease including TSAbs are closely linked to angiogenesis, which plays a crucial role

received low-dose (30-60 mCi) therapy for ablation of residual thyroid tissue. Four patients in which lateral cervical lymph node metastasis was present received high-dose (150-250 mCi) therapy.

Table 4. Parameters predicting recurrence of differentiated thyroid cancer associated with Graves’ disease

| Parameters                        | Recurrence (n=4) (%) | No recurrence (n=54) (%) | p value |
|-----------------------------------|---------------------|--------------------------|---------|
| **Gender**                        |                     |                          |         |
| Male                              | 8 (13.8)            | 46 (79.3)                | 0.411*  |
| Female                            |                     |                          |         |
| **Age (yr)**                      |                     |                          |         |
| ≥45                               | 3 (5.2)             | 15 (25.9)                |         |
| <45                               | 1 (1.7)             | 39 (67.2)                | 0.031*  |
| **Duration of thyrotoxic symptoms**|                     |                          |         |
| Serum T4 (mM/L)                   | 198.33 ± 12.13      | 209.11 ± 21.01           | 0.634†  |
| Serum T3 (mM/L)                   | 7.2 ± 0.9           | 6.9 ± 0.7                | 0.207†  |
| Thyroglobulin (μg/L)              | 20.9 ± 22.3         | 3.4 ± 27.8               | 0.273†  |
| Serum TSH (mIU/L)                 | 16.3 ± 21.1         | 12.1 ± 16.1              | 0.384†  |
| **Pathology**                     |                     |                          |         |
| Clinical cancer                   | 4 (6.9)             | 22 (37.9)                | 0.035*  |
| Incidental cancer                 | 32 (55.2)           |                          |         |
| **Tumor size (mm)**               |                     |                          |         |
| ≤10                               | 3 (5.2)             | 12 (20.7)                | 0.049*  |
| >10                               | 1 (1.7)             | 42 (72.4)                |         |
| **Extracapsular invasion**        |                     |                          |         |
| Yes                               | 4 (6.9)             | 19 (32.8)                | 0.021*  |
| No                                | 35 (60.3)           |                          |         |
| **Invasion to adjacent structure**|                     |                          |         |
| Yes                               | 1 (1.7)             | 2 (3.4)                  | 0.196*  |
| No                                | 52 (89.7)           |                          |         |
| **Multiplicity**                  |                     |                          |         |
| Yes                               | 4 (6.9)             | 14 (24.1)                | 0.007*  |
| No                                | 40 (70.0)           |                          |         |
| **Central lymph node metastasis** |                     |                          |         |
| Yes                               | 3 (5.2)             | 15 (25.9)                | 0.084*  |
| No                                | 1 (1.7)             | 39 (67.2)                |         |
| **Lateral cervical lymph node metastasis** |             |                          |         |
| Yes                               | 1 (1.7)             | 4 (6.9)                  | 0.310*  |
| No                                | 3 (5.2)             | 50 (86.2)                |         |
| **Extent of thyroidectomy**       |                     |                          |         |
| TT                                | 1 (1.7)             | 19 (32.8)                | 0.572*  |
| Less than TT                      | 3 (5.2)             | 35 (62.1)                |         |
| **Central compartment lymph node dissection** |             |                          |         |
| Yes                               | 3 (5.2)             | 15 (25.9)                | 0.084*  |
| No                                | 1 (1.7)             | 39 (67.2)                |         |
| **Postoperative 131 RI**          |                     |                          |         |
| Yes                               | 2 (3.4)             | 14 (24.1)                | 0.303*  |
| No                                | 2 (3.4)             | 40 (69.0)                |         |

Mean ± SD: median with the range presented in parenthesis.
* Fisher’s exact test; † Mann-Whitney U test; ‡ measured before antithyroid treatment; †† measured after postoperative six week.
T4, thyroxine; T3, triiodothyronine; TSH, thyroid-stimulating hormone; TT, total thyroidectomy; RI, radioactive iodine therapy.
in tumor growth and development (15, 21, 23). Therefore, patients of Graves' disease with DTC has been found to have a worse clinical outcome than euthyroid patients with DTC (4, 17, 18, 24, 25). In contrast, other investigators suggested that Graves' disease was not related to the aggressiveness of coexisting thyroid carcinoma (6, 9, 26). These studies identified that the severity of thyrotoxicosis was not related to the prognosis of DTC patients with concurrent Graves' disease (27-29). In the present series of our work, the 10-yr overall survival rate was 95.8% and 91.1%, respectively, showing favorable treatment outcomes in these patients, and the severity of thyrotoxicosis and serum thyroid hormone levels did not affect the prognosis.

A few studies examined recurrence-predicting indicators in patients of DTC with concurrent Graves' disease. Although some authors suggested patient age, tumor size and preoperative T3 levels as significant factors to predict metastasis (6, 30), recent studies indicate that the most crucial prognostic indicator is diagnostic timing (clinical or incidental) (26, 31). In the present investigation, patient age over 45 yr, the presence of extracapsular invasion, multiplicity, and clinical cancer, but not severity of thyrotoxicosis, were correlated with a high recurrence rate.

Debate continues regarding the proper extent of surgery for Graves' disease patients with DTC. There has been a preference for radical surgery in patients with DTC with concurrent Graves' disease, involving at least total thyroidectomy and lymph node dissection followed by R1 (16, 17). However, recent approaches have suggested that the choice of surgical strategies depend on the diagnostic timing and stage of tumor (26-31). This indicates that the extent of surgery should be similar for thyroid cancer in euthyroid patients, and that subtotal thyroidectomy is sufficient, whereas additional completion total thyroidectomy is not necessary in incidental cases. In the present investigation, neither the extent of thyroidectomy nor the presence of lymph node dissection was found to be correlated with the recurrence rate. Therefore, complete thyroidectomy might be helpful only in cases in which indicators predicting recurrence are present.

In conclusion, we recommend that patients of Graves' disease should undergo regular screening both meticulous physical examination and ultrasonography for early detection of thyroid carcinoma. Our present results show that predicting factors for recurrence in DTC patients with concurrent Graves' disease were age over 45 yr, tumor size over 10 mm, multiplicity, extracapsular invasion, and clinical carcinoma. We also suggest that the choice of extent of surgery in these patients should depend on the diagnostic timing (clinical or incidental) and factors for predicting recurrences, and that a subtotal thyroidectomy would be sufficient in incidental carcinomas without factors predicting recurrence. On the other hand, in clinical cancers or in cases where recurrence-predicting factors are present, at least a total thyroidectomy with lymph node dissection might be helpful.

REFERENCES

1. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 1974; 38: 976-98.

2. Pacini F, Elisi R, Di Coscio GC, Anelli S, Macchia E, Concetti R, Miccoli P, Arganini M, Pinchera A. Thyroid carcinoma in thyrotoxic patients treated by surgery. J Clin Endocrinol Invest 1988; 11: 107-12.

3. Ruggieri M, Scocchera F, Genderini M, Mascaro A, Luongo B, Paoloni A. Hyperthyroidism and concurrent thyroid carcinoma. Eur Rev Med Pharmacol Sci 1999; 6: 265-8.

4. Belfiore A, Garofalo MR, Giuffrida D, Runello F, Filetti S, Fiumara A, Ippolito O, Vigneri R. Increased aggressiveness of thyroid cancer in patients with Graves' disease. J Clin Endocrinol Metab 1990; 70: 830-5.

5. Camnell NE, Valente WA. Thyroid nodules in Graves' disease or thyrotoxicosis affect the prognosis of thyroid cancer. Thyroid 1998; 8: 571-6.

6. Hales IB, McElduff A, Crammer P, Clifton-Bligh P, Delbridge L, Hosch R, Poole A, Reeve TS, Wilmhurst E, Wiseman J. Does Graves' disease or thyrotoxicosis affect the prognosis of thyroid cancer. J Clin Endocrinol Metab 1992; 75: 886-9.

7. Prades JM, Dumollard JM, Timoshenko A, Chelík L, Michel F, Estour B, Martin C. Multinodular goiter: surgical management and histopathological findings. Eur Arch Otorhinolaryngol. 2002; 259: 217-21.

8. Belfiore A, Russo D, Vigneri R, Filetti S. Graves' disease, thyroid nodules and thyroid cancer. Clin Endocrinol (Oxf) 2001; 55: 711-8.

9. Gerenova J, Buysschaert M, de Barbure CY, Daumieric C. Prevalence of thyroid cancer in Graves' disease: a retrospective study of a cohort of 103 patients treated surgically. Eur J Med 2003; 14: 321-5.

10. Kim WB, Han SM, Kim TY, Nam-Goong IS, Gong G, Lee HK, Hoong SJ, Shong YK. Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease. Clin Endocrinol (Oxf) 2004; 60: 719-25.
Differentiated Thyroid Cancer in Patients with Graves’ Disease

11. Olen E, Klinck GH. Hyperthyroidism and thyroid cancer. Arch Pathol 1966; 81: 531-5.
12. Nicolosi A, Addis E, Calo PG, Tarquini A. Hyperthyroidism and cancer of the thyroid. Minerva Chir 1994; 49: 491-5.
13. Ragni F, Pinelli D, Facchini M, Ghedi M, Piccini I, Pasini M, Roncali S, Pezzola D, Braga M. Thyroid carcinoma in hyperthyroid syndrome. G Chir 1996; 17: 158-65.
14. Farbota LM, Calandra DB, Lawrence AM, Paloyan E. Thyroid carcinoma in Graves’ disease. Surgery 1985; 98: 1148-53.
15. Sato K, Yamazaki K, Shizume K, Kanaji Y, Obara T, Ohsami K, Demura H, Yamaguchi S, Shibuya M. Stimulation by thyroid-stimulating hormone and Graves’ immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Invest 1995; 96: 1295-302.
16. Kashima K, Yokoyama S, Daat T, Takashashi K, Nakayama I, Noguchi S. C-myc expression is associated with increased proliferation activity in thyroid follicle cells of Graves’ disease as stimulated by autoantibodies. Eur J Endocrinol 1996; 135: 69-76.
17. Pellegriti G, Belfiore A, Giuffrida D, Lupo L, Vigneri R. Outcome of differentiated thyroid cancer in Graves’ patients. J Clin Endocrinol Metab 1998; 83: 2805-9.
18. Kikuchi S, Noguchi S, Yamashita H, Uchino S, Kawamoto H. Progress of small thyroid cancer in patients with Graves’ disease. Br J Surg 2006; 93: 434-9.
19. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM. AJCC Cancer Staging Manual, 6th edn. Chicago: Springer Verlag, 2003.
20. Behar R, Arganini M, Wu TC, McCormick M, Straus FH 2nd, Degroot LJ, Kaplan EL. Graves’ disease and thyroid cancer. Surgery 1986; 100: 1121-7.
21. Filetti S, Belfiore A, Amir SM, Daniels GH, Ippolito O, Vigneri R, Ingbar SH. The role of thyroid-stimulating antibodies of Graves’ disease in differentiated thyroid cancer. N Engl J Med 1988; 318: 753-9.
22. Van Sande J, Lejeune C, Ladagate M, Munro DS, Vassart G, Dumont JE, Mockel J. Thyroid stimulating immunoglobulins, like thyrotropin activate both the cyclic AMP and the PI3K cascades in CHO cells expressing the TSH receptor. Mol Cell Endocrinol 1992; 88: R1-5.
23. Viglietto G, Romano A, Manzo G, Chiappetta G, Pasolli I, Califano D, Galati MG, Mauriello V, Bruni P, Lago CT, Fusco A, Persico MG. Upregulation of the angiogenic factors PIGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thioucaril-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 1997; 15: 2678-98.
24. Stocker DJ, Burch HB. Thyroid cancer yield in patients with Graves’ disease. Minerva Endocrinol 2003; 28: 205-12.
25. Cappelli C, Braga M, De Martino E, Castellano M, Gandossi E, Agosti B, Cumetti D, Firola I, Mattanza C, Cherubini L, Rosei EA. Outcome of patients surgically treated for various forms of hyperthyroidism with differentiated thyroid cancer: Experience at an endocrine center in Italy. Surg Today 2006; 36: 125-30.
26. Duh QY. Thyroid cancer in Graves disease: Incidental cancer versus clinical cancer. Ann Surg Oncol 2004; 11: 356-7.
27. Miki H, Oshimo K, Inoue H, Kawano M, Tanaka K, Komaki K, Uyama T, Monden Y. Diagnosis and surgical treatment of small papillary carcinoma of the thyroid gland. J Surg Oncol 1993; 54: 78-80.
28. Soh EY, Jung WH, Park CS. Thyroid carcinoma in Graves’ disease: Clinical features and diagnostic approach. J. Korean Med Assoc 1991; 34: 1229-35.
29. Yeo PP, Wang KW, Sinniah R, Aw TC, Chang CH, Sethi VK, Tan BC, Lim P. Thyrotoxicosis and thyroid cancer. Aust N Z J Med 1982; 12: 589-93.
30. Chao TC, Lin JD, Chen MF. Surgical treatment of thyroid cancers with concurrent Graves disease. Ann Surg Oncol 2004; 11: 407-12.
31. Yano Y, Shibuya H, Kitagawa W, Nagahama M, Sugino K, Ito K, Ito K. Recent outcome of Graves’ disease patients with papillary thyroid cancer. Eur J Endocrinol 2007; 157: 325-9.